{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:26:54Z","timestamp":1793370414163,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"am","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008231","name":"Arkansas Biosciences Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008231","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","award":["1I21HX003268-01A1"],"award-info":[{"award-number":["1I21HX003268-01A1"]}],"id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR003107"],"award-info":[{"award-number":["UL1 TR003107"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR001427"],"award-info":[{"award-number":["UL1 TR001427"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR000064"],"award-info":[{"award-number":["UL1 TR000064"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"VHA Health Services Research & Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA248972"],"award-info":[{"award-number":["K08CA248972"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.eprac.2024.12.011","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T20:18:54Z","timestamp":1734380334000},"page":"455-464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Predictive Model for Graves\u2019 Disease Recurrence After Antithyroid Drug Therapy: A Retrospective Multicenter Cohort Study"],"prefix":"10.1016","volume":"31","author":[{"given":"Omar","family":"El Kawkgi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Toro-Tobon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy J.K.","family":"Toloza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Vallejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian Soto","family":"Jacome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan N.","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan A.","family":"Vallejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Wenczenovicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Tzeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horace J.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff D.","family":"Thostenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Kohlenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Lincango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Castellanos-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridoula","family":"Maraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naykky Singh","family":"Ospina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2024.12.011_bib1","series-title":"Endotext","article-title":"Graves\u2019 disease and the manifestations of thyrotoxicosis","author":"Toro-Tobon","year":"2000"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.011_bib2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1530\/EJE-20-1490","article-title":"Preferences of patients and clinicians for treatment of Graves' disease: a discrete choice experiment","volume":"184","author":"van Kinschot","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.011_bib3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12020-022-02989-x","article-title":"Individualized Graves' disease remission rates conversations: a videographic analysis of medical encounters","volume":"76","author":"Hidalgo","year":"2022","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.011_bib4","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1210\/jc.2015-3644","article-title":"Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves' hyperthyroidism","volume":"101","author":"Vos","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eprac.2024.12.011_bib5","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s40618-018-0918-9","article-title":"Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management","volume":"41","author":"Masiello","year":"2018","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.eprac.2024.12.011_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.756560","article-title":"Identification of lncRNA and mRNA expression profile in relapsed Graves' disease","volume":"9","author":"Yao","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.eprac.2024.12.011_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.761077","article-title":"Recurrence of Graves' disease: what genetics of HLA and PTPN22 can tell us","volume":"12","author":"Vejrazkova","year":"2021","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.011_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/009286150303700112","article-title":"The statistical basis of laboratory data normalization","volume":"37","author":"Karvanen","year":"2003","journal-title":"Drug Inf J"},{"issue":"5","key":"10.1016\/j.eprac.2024.12.011_bib9","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/cen.14719","article-title":"Postradioiodine Graves' management: the PRAGMA study","volume":"97","author":"Perros","year":"2022","journal-title":"Clin Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2024.12.011_bib10","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.011_bib11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/thy.2016.0343","article-title":"Comparative effectiveness of treatment choices for Graves' hyperthyroidism: a historical cohort study","volume":"27","author":"Sundaresh","year":"2017","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.eprac.2024.12.011_bib12","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1089\/thy.2020.0881","article-title":"Does age or sex relate to severity or treatment prognosis in Graves' disease?","volume":"31","author":"Suzuki","year":"2021","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.011_bib13","article-title":"Serum T3 level and duration of minimum maintenance dose therapy predict relapse n methimazole-treated Graves disease","volume":"5","author":"Thewjitcharoen","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"issue":"9","key":"10.1016\/j.eprac.2024.12.011_bib14","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1089\/thy.2019.0180","article-title":"Increased remission rates after long-term methimazole therapy in patients with Graves' disease: results of a randomized clinical trial","volume":"29","author":"Azizi","year":"2019","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.011_bib15","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.clinthera.2020.01.022","article-title":"Risk factors for the relapse of Graves' disease treated with antithyroid drugs: a systematic review and meta-analysis","volume":"42","author":"Shi","year":"2020","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.eprac.2024.12.011_bib16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1055\/a-0974-3991","article-title":"External validation of the GREAT score in Turkish patients with Graves' hyperthyroidism treated with the titration regimen method of antithyroid drugs: a multicenter study","volume":"51","author":"Zuhur","year":"2019","journal-title":"Horm Metab Res"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.011_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1530\/EJE-16-0725","article-title":"Can we predict relapse in Graves' disease? Results from a systematic review and meta-analysis","volume":"176","author":"Struja","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.011_bib18","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0226","article-title":"Long-term follow-up result of antithyroid drug treatment of Graves' hyperthyroidism in a large cohort","volume":"12","author":"Jin","year":"2023","journal-title":"Eur Thyroid J"},{"issue":"9","key":"10.1016\/j.eprac.2024.12.011_bib19","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.4158\/EP-2020-0035","article-title":"Thyroid peroxidase antibody positivity is associated with relapse-free survival following antithyroid drug treatment for Graves disease","volume":"26","author":"Muir","year":"2020","journal-title":"Endocr Pract"},{"issue":"10","key":"10.1016\/j.eprac.2024.12.011_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24701","article-title":"High levels of thyroid hormones promote recurrence of Graves' disease via overexpression of B-cell-activating factor","volume":"36","author":"Liu","year":"2022","journal-title":"J\u00a0Clin Lab Anal"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.011_bib21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12020-021-02725-x","article-title":"The longer the antithyroid drug is used, the lower the relapse rate in Graves' disease: a retrospective multicenter cohort study in Korea","volume":"74","author":"Park","year":"2021","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.011_bib22","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-013-9895-0","article-title":"Predictors of long-term remission in patients with Graves' disease: a single center experience","volume":"44","author":"Anagnostis","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.eprac.2024.12.011_bib23","doi-asserted-by":"crossref","DOI":"10.5812\/ijem.101139","article-title":"Long-term antithyroid drug treatment: trends in serum TSH and TRAb changes in patients with Graves\u2019 disease","author":"Okamura","year":"2020","journal-title":"Int J Endocrinol Metabol"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.011_bib24","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s40618-021-01730-1","article-title":"Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: a systematic scoping review","volume":"45","author":"Azizi","year":"2022","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.011_bib25","article-title":"Thyroid-stimulatory antibody as a predictive factor for Graves' disease relapse","volume":"14","author":"Da Silva Santos","year":"2022","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.eprac.2024.12.011_bib26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1530\/eje.0.1440475","article-title":"Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study","volume":"144","author":"Glinoer","year":"2001","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2024.12.011_bib27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/eje.0.1470583","article-title":"Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease","volume":"147","author":"Nedrebo","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2024.12.011_bib28","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1210\/jc.2018-01738","article-title":"Age may influence the impact of TRAbs on thyroid function and relapse-risk in patients with Graves disease","volume":"104","author":"Bano","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.011_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1055\/s-2004-814217","article-title":"Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease","volume":"36","author":"Schott","year":"2004","journal-title":"Horm Metab Res"},{"issue":"8","key":"10.1016\/j.eprac.2024.12.011_bib30","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1089\/thy.2016.0017","article-title":"Thyrotropin receptor antibody levels at diagnosis and after thionamide course predict Graves' disease relapse","volume":"26","author":"Tun","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.eprac.2024.12.011_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/20420188211044943","article-title":"The prognostic value of thyroid-stimulating immunoglobulin in the management of Graves' disease","volume":"12","author":"Zhou","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2024.12.011_bib32","article-title":"The prediction model using thyroid-stimulating immunoglobulin bioassay for relapse of Graves' disease","volume":"6","author":"Baek","year":"2022","journal-title":"J\u00a0Endocr Soc"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.011_bib33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1055\/a-1373-5523","article-title":"Predicting the relapse of hyperthyroidism in treated Graves' disease with orbitopathy by serial measurements of TSH-receptor autoantibodies","volume":"53","author":"St\u00f6hr","year":"2021","journal-title":"Horm Metab Res"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.011_bib34","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02933.x","article-title":"Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission","volume":"67","author":"Eckstein","year":"2007","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.011_bib35","doi-asserted-by":"crossref","DOI":"10.20945\/2359-3997000000609","article-title":"Prediction for recurrence following antithyroid drug therapy for Graves' hyperthyroidism","volume":"67","author":"Weng","year":"2023","journal-title":"Arch Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.011_bib36","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ando.2015.08.004","article-title":"Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment","volume":"76","author":"Liu","year":"2015","journal-title":"Ann Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2024.12.011_bib37","first-page":"427","article-title":"Independent pretreatment predictors of Graves' disease outcome","volume":"49","author":"Dauk\u0161ien\u0117","year":"2013","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.011_bib38","first-page":"207","article-title":"The effect of gender on response to antithyroid drugs and risk of relapse after discontinuation of the antithyroid drugs in patients with Graves' hyperthyroidism: a multicentre study","volume":"71","author":"Zuhur","year":"2020","journal-title":"Endokrynol Pol"},{"issue":"11","key":"10.1016\/j.eprac.2024.12.011_bib39","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.4158\/EP161350.OR","article-title":"Gender influences the clinical presentation and long-term outcome of graves disease","volume":"22","author":"Magri","year":"2016","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.011_bib40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF03343979","article-title":"Does smoking increase relapse rates in Graves' disease?","volume":"25","author":"Kimball","year":"2002","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"9","key":"10.1016\/j.eprac.2024.12.011_bib41","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1089\/thy.2009.0126","article-title":"Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease","volume":"20","author":"Choo","year":"2010","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.011_bib42","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3803\/EnM.2023.1664","article-title":"The early changes in thyroid-stimulating immunoglobulin bioassay over anti-thyroid drug treatment could predict prognosis of Graves' disease","volume":"38","author":"Yu","year":"2023","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.011_bib43","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/EJE-16-0986","article-title":"External validation of the GREAT score to predict relapse risk in Graves' disease: results from a multicenter, retrospective study with 741 patients","volume":"176","author":"Struja","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.011_bib44","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2362.2004.01318.x","article-title":"Use of an artificial neural network to predict Graves' disease outcome within 2 years of drug withdrawal","volume":"34","author":"Orunesu","year":"2004","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"10.1016\/j.eprac.2024.12.011_bib45","doi-asserted-by":"crossref","first-page":"E1080","DOI":"10.1210\/jc.2011-2897","article-title":"A\u00a0TSHR-LH\/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment","volume":"97","author":"Giuliani","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.011_bib46","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1210\/jc.2017-02318","article-title":"A\u00a0MicroRNA signature for evaluation of risk and severity of autoimmune thyroid diseases","volume":"103","author":"Mart\u00ednez-Hern\u00e1ndez","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.011_bib47","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-0043-100116","article-title":"MiR-346 and TRAb as predicative factors for relapse in Graves' disease within one year","volume":"49","author":"Li","year":"2017","journal-title":"Horm Metab Res"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.011_bib48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/thy.2017.0244","article-title":"Sialic acid-binding immunoglobulin-like Lectin1 as a novel predictive biomarker for relapse in Graves' disease: a multicenter study","volume":"28","author":"Hashimoto","year":"2018","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.011_bib49","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1210\/jc.2003-030854","article-title":"Cytotoxic T lymphocyte-associated molecule-4 polymorphism and relapse of Graves' hyperthyroidism after antithyroid withdrawal","volume":"89","author":"Wang","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2024.12.011_bib50","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejim.2005.06.007","article-title":"Cytotoxic T lymphocyte-associated molecule-4 polymorphisms in Turkish Graves' disease patients and association with probability of remission after antithyroid therapy","volume":"16","author":"Sahin","year":"2005","journal-title":"Eur J Intern Med"},{"issue":"7","key":"10.1016\/j.eprac.2024.12.011_bib51","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1210\/jc.2006-2761","article-title":"Cytotoxic T lymphocyte-associated molecule-4 gene polymorphism and hyperthyroid Graves' disease relapse after antithyroid drug withdrawal: a follow-up study","volume":"92","author":"Wang","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.12.011_bib52","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3389\/fendo.2018.00623","article-title":"Metabolomics for prediction of relapse in Graves' disease: observational pilot study","volume":"9","author":"Struja","year":"2018","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.011_bib53","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11154-016-9386-8","article-title":"Relapse prediction in Graves' disease: towards mathematical modeling of clinical, immune and genetic markers","volume":"17","author":"Langenstein","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"issue":"8","key":"10.1016\/j.eprac.2024.12.011_bib54","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1089\/thy.2023.0132","article-title":"Artificial intelligence in thyroidology: a narrative review of the current applications, associated challenges, and future directions","volume":"33","author":"Toro-Tobon","year":"2023","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.011_bib55","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1507\/endocrj.EJ18-0418","article-title":"The long-term follow-up of patients with thionamide-treated Graves' hyperthyroidism","volume":"66","author":"Bandai","year":"2019","journal-title":"Endocr J"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:57:51Z","timestamp":1762549071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24008693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1530891X24008693"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.12.011","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Predictive Model for Graves\u2019 Disease Recurrence After Antithyroid Drug Therapy: A Retrospective Multicenter Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}